New injection shows promise for rare High-Fat disease
NCT ID NCT05902598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tested a drug called Plozasiran in 37 Chinese adults with Familial Chylomicronemia Syndrome (FCS), a rare condition causing extremely high blood fats. The trial compared the drug to a placebo over about two years, measuring how much it lowered triglyceride levels. All participants who finished could then receive the drug in an open-label extension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Plozasiran (a drug injection that targets a protein to lower blood fats)
- What this could lead to
- If it works, this could provide a new treatment option to control severe high triglycerides and reduce risk of pancreatitis in people with Familial Chylomicronemia Syndrome.
- What could go wrong
- This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. The drug may cause side effects or fail to show lasting benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.